Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04294147 · ClinicalTrials.gov registry record · Phase 4
A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist
A Phase 4 study of Migraine, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 65
- Enrollment target
- 3
- Study locations
NCT04294147 is a Phase 4 study of Migraine that has completed, run by Eli Lilly and Company. The registered enrollment target is 65 participants, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (82% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT04294147, a Phase 4 study of Migraine, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 65 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to measure the gastrointestinal emptying time using the wireless motility capsule (WMC) technology (FDA approved SmartPill™) in adult participants with migraine who are taking a monoclonal antibody (mAb) calcitonin gene-related peptide (CGRP) antagonist called galcanezumab or erenumab.
Conditions Studied
Interventions
- DRUG Galcanezumab
- DRUG Erenumab
Study Locations (3)
California
- Clinical Research Institute LLC - Los Angeles
- Pharmacology Research Institute - Newport Beach
Connecticut
- CMR of Greater New Haven - Waterbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2020-10-06 |
| Est. Completion | 2021-03-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04294147
The ClinicalTrials.gov registry entry for NCT04294147 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (82% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Galcanezumab is the first listed.
NCT04294147 reports 3 study locations spanning 2 distinct geographic areas - top geographies include California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT04294147 about?
NCT04294147 is a clinical study titled "A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist". The purpose of this study is to measure the gastrointestinal emptying time using the wireless motility capsule (WMC) technology (FDA approved SmartPill™) in adult participants with migraine who are taking a monoclonal antibody (mAb) calcitonin gene-related peptide (CGRP) antagonist called galcanezum...
What is the current status of trial NCT04294147?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 65 participants. The study started on 2020-10-06. Estimated completion is 2021-03-05.
What conditions does trial NCT04294147 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT04294147?
The interventions under investigation include: Galcanezumab (DRUG), Erenumab (DRUG).
Who is sponsoring clinical trial NCT04294147?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04294147 being conducted?
This trial has 3 study locations across California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
RECRUITING · Phase 4
-
Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications
RECRUITING · Phase 4
-
Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US
RECRUITING · Phase 4
-
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
RECRUITING · Phase 4
-
Nerivio Efficacy Under High-Frequency Use
ACTIVE NOT RECRUITING · Phase 4
-
Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.